Literature DB >> 10359017

New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism.

D F Horrobin1, C N Bennett.   

Abstract

Phospholipids make up about 60% of the brain's dry weight. In spite of this, phospholipid metabolism has received relatively little attention from those seeking genetic factors involved in psychiatric and neurological disorders. However, there is now increasing evidence from many quarters that abnormal phospholipid and related fatty acid metabolism may contribute to illnesses such as schizophrenia, bipolar disorder, depression and attention deficit hyperactivity disorder. To date the possible specific proteins and genes involved have been relatively ill-defined. This paper reviews the main pathways of phospholipid metabolism, emphasizing the roles of phospholipases of the A2 and C series in signal transduction processes. It identifies some likely protein candidates for involvement in psychiatric and neurological disorders. It also reviews the chromosomal locations of regions likely to be involved in these disorders, and relates these to the known locations of genes directly or indirectly involved in phospholipid and fatty acid metabolism.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359017     DOI: 10.1054/plef.1999.0027

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  14 in total

1.  Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders.

Authors:  E A Thomas; B Dean; G Pavey; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.

Authors:  Diogo R Lara
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

Review 3.  The neurobiology of apolipoproteins in psychiatric disorders.

Authors:  J Gregor Sutcliffe; Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

4.  Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22.

Authors:  Michael L Mimmack; Margaret Ryan; Hajime Baba; Juani Navarro-Ruiz; Shuji Iritani; Richard L M Faull; Peter J McKenna; Peter B Jones; Heii Arai; Michael Starkey; Piers C Emson; Sabine Bahn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

5.  BRAIN MYELINATION IN PREVALENT NEUROPSYCHIATRIC DEVELOPMENTAL DISORDERS: PRIMARY AND COMORBID ADDICTION.

Authors:  George Bartzokis
Journal:  Adolesc Psychiatry       Date:  2005

Review 6.  Neurological benefits of omega-3 fatty acids.

Authors:  S C Dyall; A T Michael-Titus
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

7.  Association between BanI genotype and increased phospholipase A2 activity in schizophrenia.

Authors:  Nadia R Barbosa; Ricardo M Junqueira; Homero P Vallada; Wagner F Gattaz
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

8.  Psychoses and creativity: is the missing link a biological mechanism related to phospholipids turnover?

Authors:  Bradley S Folley; Mikisha L Doop; Sohee Park
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-12       Impact factor: 4.006

9.  Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia.

Authors:  Afaf K El-Ansary; Abir G Ben Bacha; Layla Y Al-Ayahdi
Journal:  Lipids Health Dis       Date:  2011-04-22       Impact factor: 3.876

10.  Sodium salicylate suppresses GABAergic inhibitory activity in neurons of rodent dorsal raphe nucleus.

Authors:  Yan Jin; Bin Luo; Yan-Yan Su; Xin-Xing Wang; Liang Chen; Ming Wang; Wei-Wen Wang; Lin Chen
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.